17.06.22

MONTRÉAL, June 17, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has submitted…

13.06.22

MONTRÉAL, June 13, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that key findings will…

13.04.22

MONTREAL, April 13, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today the publication of a…

07.04.22

MONTRÉAL, April 7, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that David Millette, Co-Chief…

15.03.22

MONTRÉAL, March 15, 2022 – ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that new…

10.03.22

MONTRÉAL, March 10, 2022 – ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that the…

21.12.21

MONTRÉAL, December 21, 2021 – ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has…

29.11.21

MONTRÉAL, November 29, 2021 – ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that new data…

09.11.21

MONTREAL, November 9, 2021 – ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that its…

13.07.21

MONTREAL, July 13, 2021 – ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that it has entered into a licensing agreement with Astellas Pharma…

21.04.21

MONTREAL, April 21, 2021 – ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, and Ossium Health, a therapeutics company harnessing the power of stem cell…

07.01.21

MONTRÉAL, January 7, 2021 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of new data describing the mechanism of action of UM171,…

11.12.20

MONTRÉAL, December 11, 2020 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that ECT-001 Cell Therapy has been granted PRIority MEdicines (PRIME) designation by…

20.10.20

MONTRÉAL, October 20, 2020 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has received Advanced Therapy Medicinal Product (ATMP) classification from the…

18.08.20

MONTREAL, August 18, 2020 – ExCellThera Inc., a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that additional data from a Phase I/II clinical trial…

15.07.20

MONTREAL, July 15, 2020 – ExCellThera Inc., a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the appointment of Richard Cherney to its Board of…

03.06.20

MONTRÉAL, JUNE 3, 2020 – ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today new appointments to its Board of Directors and Scientific Advisory…

19.05.20

MONTRÉAL, May 19, 2020 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has received a grant from the California Institute for Regenerative…

30.04.20

MONTREAL, April 30, 2020 — ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the European Medicines Agency has granted orphan medicinal product designation as…

25.02.20

MONTREAL, February 25, 2020 – ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, recently announced preliminary data from the Phase 2 trial of its ECT-001 Cell Therapy…

26.11.19

MONTRÉAL, November 26, 2019 – ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that data from a Phase I/II clinical trial using its lead technology, ECT-001,…

05.11.19

MONTRÉAL, November 5, 2019 – ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of full data from the first clinical trial using ECT-001 (single…

11.09.19

MONTREAL, September 11, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that Guy Sauvageau, President and CEO, will present a company update…

23.04.19

MONTREAL, April 23, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative…

25.03.19

MONTREAL, March 25, 2019 – ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that its lead technology, ECT-001, will be used as part of two…

17.12.18

MONTREAL, December 17, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted the ExCellThera’s lead solution,…

04.12.18

MONTREAL, December 4, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced results from the Phase I/II clinical trial using its lead technology, ECT-001, for allogeneic…

08.11.18

MONTREAL, November 8, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that results from the Phase I/II clinical trial using its lead technology, ECT-001, for…

27.06.18

MONTREAL, June 27, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today the close of its initial, 25-patient clinical trial for its lead technology, ECT-001. The final…

14.05.18

(le français suit) MONTREAL, May 14, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today that its lead platform, ECT-001, will be used as part of a…

22.03.18

(le français suit) MONTREAL, March 22, 2018 – ExCellThera Inc. announced today the appointment of David Millette as Chief Financial and Legal Officer effective April 3, 2018. Mr. Millette combines a solid background in finance and law, having practised in…